![]() ![]() Selected prior board memberships include Aimmune (AIMT, acquired by Nestlé Health Science), Codexis (CDXS), Corcept Therapeutics (CORT), Dascena, Esperion Therapeutics (ESPR), Horizon Pharmaceuticals (HZNP), InfaCare Pharmaceutical (acquired by Mallinckrodt), MAP Pharmaceuticals (MAPP, acquired by Allergan), Prestwick Pharmaceuticals (acquired by Lundbeck), Sequenom (SQNM, acquired by LabCorp), Threshold Pharmaceuticals (THLD), and Vaxcyte (PCVX). Enright currently serves on the boards of Aptinyx (APTX), CuraSen Therapeutics, Endeavor Biomedicines, Epirium Bio, Jazz Pharmaceuticals (JAZZ), Orbus Therapeutics, Rivus Pharmaceuticals, Vera Therapeutics (VERA), as well as the National Venture Capital Association (NVCA). ![]() Enright also has significant life sciences operations experience, including senior executive positions at Valentis (VLTS), Boehringer Mannheim (acquired by Roche), and Sandoz (now known as Novartis). Enright began his investment career at PaineWebber Development Corporation. Prior to Pequot, he was a Managing Member of the Delta Opportunity Fund at Diaz & Altschul Capital Management. Enright was a Managing Director of Pequot Ventures, where he co-led the life sciences investment practice. Enright is a Managing Director and Founder of Longitude Capital. Diaz holds an MBA from Harvard Business School and a BA from Harvard University.įocus Areas: Biotechnology (including royalty transactions) Diaz started his career at PaineWebber, where he was a key member of the PaineWebber Healthcare Investment Banking Group and President of PaineWebber Development Corporation. Diaz was a Managing Director and Head of the Healthcare group at Schroder Wertheim & Co. Prior to joining Auven Therapeutics, he was a Managing Member and co-founder of Diaz & Altschul Capital Management (D&A Capital). In addition, he consults for various companies in the healthcare industry, including Auven Therapeutics, where he previously served as Managing Director from 2008 to 2018. Diaz serves on the boards of Lexeo Therapeutics, Inozyme (INZY), and is the part-time Chief Business Officer of Opna-IO, a Longitude Capital portfolio company. Diaz is a Venture Partner of Longitude Capital. Bakker holds an MPA from the Harvard Kennedy School and a BSc from the College of Agriculture and Life Sciences (”CALS”) at Cornell University, where she is a member of the CALS Advisory Council.įocus Areas: Medical Technology, Health Solutions ![]() Bard), Insulet (PODD), Precision Dermatology (acquired by Valeant Pharmaceuticals), Sadra Medical (acquired by Boston Scientific), and Venus Concept (VERO). Selected prior board memberships include Ablation Frontiers (acquired by Medtronic), Alphaeon, AqueSys (acquired by Allergan), Axonics Modulation Technologies (AXNX), CryoVascular Systems (acquired by Boston Scientific), Eargo (EAR), Embolic Protection (acquired by Boston Scientific), Enteric Medical (acquired by Boston Scientific), eyeonics (acquired by Bausch+Lomb), Genyx Medical (acquired by C.R. She currently serves on the boards of Ceribell, Endogenex, Nalu, and RxSight (RXST). Bakker began her career as an investment banker in the corporate finance department at PaineWebber. Prior to Pequot, she was Director, Strategic Planning and Director, Operations of Waste Management International, and was a sell-side equity analyst with Banque Paribas. Bakker was a Managing Director of Pequot Ventures, where she founded the life sciences investment practice. Bakker is a Managing Director and Founder of Longitude Capital. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |